Clinical trials: Eye Manifestations
Progressive Supranuclear Palsy
A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy.
- Trial name
- NCT04008355
- Testing
- AZP2006 oral solution
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- AlzProtect SAS
Blindness
A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury
The BrainPort V200 Device is a wearable, non-surgical, prosthetic device intended for people who are profoundly blind. The BrainPort V200 translates images captured by a digital camera into electro-tactile stimulation presented…
- Trial name
- NCT02393118
- Testing
- BrainPort V200 Device
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wicab
Neuropathic Corneal Pain
Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).
This study is testing a new investigational study drug called Urcosimod Ophthalmic Solution for the treatment of Neuropathic Corneal Pain (NCP).
- Trial name
- NEPTUNE (NCT07838506)
- Testing
- Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Okyo Pharma Ltd
Retinitis Pigmentosa, Retinitis
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines.
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases
- Trial name
- REMAIN (NCT06162585)
- Testing
- Gene Therapy product-MCO-010
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- Nanoscope Therapeutics Inc.
Vision Loss Night, Vision Disorders
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions.
- Trial name
- LYNX-3 (NCT07140783)
- Testing
- 0.75% Phentolamine Ophthalmic Solution
- Where
- 20 sites in United States
- Volunteers
- 580 people
- Sponsor
- Opus Genetics, Inc
Progressive Supranuclear Palsy
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for…
- Trial name
- NCT06355531
- Testing
- FNP-223
- Where
- 44 sites in United States, France and 7 more
- Volunteers
- 241 people
- Sponsor
- Ferrer Internacional S.A.
TNF-receptor Associated Periodic Syndromes (TRAPS)
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
- Trial name
- NCT01242813
- Testing
- ACZ885
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06723106
- Testing
- RAY121
- Where
- 62 sites in Australia, Austria and 17 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Cataract, Anterior Chamber Inflammation
Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery
Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber…
- Conditions
- Cataract, Anterior Chamber Inflammation, Pain, Postoperative
- Trial name
- NCT03180255
- Testing
- Dexamethasone phosphate
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Retinitis Pigmentosa, Usher Syndromes
Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa
This study is aimed to characterize Russian population of Retinitis Pigmentosa
- Trial name
- RU-RP (NCT03901391)
- Testing
- Whole Exome Sequencing
- Where
- 2 sites in Russia
- Volunteers
- 130 people
- Sponsor
- Sensor Technology for Deafblind
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02508337
- Testing
- XG-102
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- Xigen SA
Increased Lordosis/Scoliosis, Hyporeflexia
Biomarker for Duchenne Muscular Dystrophy
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
- Conditions
- Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness
- Trial name
- BioDuchenne (NCT02994030)
- Where
- 12 sites in Albania, Egypt and 6 more
- Volunteers
- 103 people
- Sponsor
- CENTOGENE GmbH Rostock
Paralysis, Paralysis; Eye
Evaluate the Usability of the Neuro-trigger Artificial Eye Blinking Stimulation Device in Patients With Paralysis of the Facial Nerve.
This is a single-center, open-label clinical study. Up to 11 subjects will be enrolled to use the Neuro-trigger device for blinking stimulation for a duration of 14 days.
- Conditions
- Paralysis, Paralysis; Eye, Paralysis; Bell
- Trial name
- paralysis (NCT06069128)
- Testing
- Neurotrigger Basic. eye blinking stimulator
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Neurotrigger Ltd
Myopia, Myopia, Progressive
Kubota Glass Parameter Refinement Study
Length of the eye will be measured in subjects exposed to various stimulus characteristics using an electronic spectacle which presents illuminated targets to the eye.
- Conditions
- Myopia, Myopia, Progressive, Vision Disorders
- Trial name
- NCT06085430
- Testing
- Kubota Glass
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Usher Syndrome, Retinitis Pigmentosa
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
To evaluate the safety and tolerability of ascending doses of subretinal injections of SAR421869 in participants with Usher syndrome type 1B. To evaluate for possible biological activity of SAR421869.
- Trial name
- NCT01505062
- Testing
- SAR421869
- Where
- 2 sites in United States, France
- Volunteers
- 9 people
- Sponsor
- Sanofi
Vision Disorders
Pilot Clinical Evaluation of Approved Contact Lenses
This is a pilot evaluation to assess the feasibility of using novel imaging process to characterize lens edge and limbal epithelial thickness profile; lens movement with gaze and blink; and conjunctival microvasculature including…
- Trial name
- NCT02540122
- Testing
- Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Blindness and Low Vision
A Pilot Study Comparing Performance of Blind Participants on 12 Tasks, With and Without the ARIA Device
Summary The environment in which we live, play and travel is primarily built by and for people with sight. Navigating the sighted world with blindness can be exhausting, as it involves disorientation, social isolation, increased…
- Trial name
- NCT06477809
- Testing
- ARIA Glasses ( Augmented Reality in Audio )
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- ARIA Research Pty Ltd
Myopia, Amblyopia
Real Word Study on Myopia Control With Repeated Red Light Therapy for Ages of 3~6 Years Old
Repeated Red Light Therapy had been used as an amblyopia therapy for children as well as the myopia control in primary schools. However, ultra low lever of red light therapy with irradiance of 0.37mW and 0.60mW effectiveness and…
- Trial name
- RMC (NCT05811598)
- Testing
- repeated ultra low lever red light
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Dry Age-related Macular Degeneration, Vision Impairment and Blindness
Vision Improvement for Legally Blind Dry AMD Patients
This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.
- Trial name
- NCT04875234
- Testing
- Clear-K Low Vision Aid Treatment
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Retinitis Pigmentosa (RP), Usher Syndrome
Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease.
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome, Cone Rod Dystrophy
- Trial name
- TES-STEP (NCT07548944)
- Testing
- Transcorneal Electrical Stimulation using the OkuStim System
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Okuvision GmbH